Daniela Žáčková

600 total citations
34 papers, 175 citations indexed

About

Daniela Žáčková is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Daniela Žáčková has authored 34 papers receiving a total of 175 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 21 papers in Genetics and 9 papers in Rheumatology. Recurrent topics in Daniela Žáčková's work include Chronic Myeloid Leukemia Treatments (31 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Eosinophilic Disorders and Syndromes (9 papers). Daniela Žáčková is often cited by papers focused on Chronic Myeloid Leukemia Treatments (31 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Eosinophilic Disorders and Syndromes (9 papers). Daniela Žáčková collaborates with scholars based in Czechia, France and Netherlands. Daniela Žáčková's co-authors include Jiřı́ Mayer, Zdeněk Ráčil, Tomáš Jurček, Dana Dvořáková, Filip Rázga, Hana Klamová, Kateřina Machová Poláková, J Voglová, Zdeněk Pospı́šil and Gregor Eisenwort and has published in prestigious journals such as Blood, Cellular and Molecular Life Sciences and British Journal of Haematology.

In The Last Decade

Daniela Žáčková

26 papers receiving 169 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniela Žáčková Czechia 8 140 109 45 40 25 34 175
Simone Claudiani United Kingdom 8 165 1.2× 136 1.2× 49 1.1× 45 1.1× 19 0.8× 31 209
Alicia Enrico Argentina 5 198 1.4× 177 1.6× 117 2.6× 33 0.8× 21 0.8× 13 227
Fabian Lang Germany 8 227 1.6× 164 1.5× 69 1.5× 53 1.3× 67 2.7× 39 285
Jeffrey Skinner United States 6 188 1.3× 162 1.5× 94 2.1× 40 1.0× 24 1.0× 16 220
Rabia Shahswar Germany 6 157 1.1× 120 1.1× 41 0.9× 15 0.4× 68 2.7× 12 185
Odoardo Maria Olimpieri Italy 8 105 0.8× 109 1.0× 50 1.1× 46 1.1× 96 3.8× 11 222
Gioia Colafigli Italy 11 270 1.9× 178 1.6× 61 1.4× 54 1.4× 99 4.0× 41 333
Franck E. Nicolini France 3 180 1.3× 160 1.5× 117 2.6× 15 0.4× 11 0.4× 6 190
Jana Linhartová Czechia 7 191 1.4× 120 1.1× 37 0.8× 45 1.1× 46 1.8× 13 242
Cristina Bucelli Italy 9 173 1.2× 162 1.5× 73 1.6× 34 0.8× 81 3.2× 33 250

Countries citing papers authored by Daniela Žáčková

Since Specialization
Citations

This map shows the geographic impact of Daniela Žáčková's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Žáčková with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Žáčková more than expected).

Fields of papers citing papers by Daniela Žáčková

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Žáčková. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Žáčková. The network helps show where Daniela Žáčková may publish in the future.

Co-authorship network of co-authors of Daniela Žáčková

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Žáčková. A scholar is included among the top collaborators of Daniela Žáčková based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Žáčková. Daniela Žáčková is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Žáčková, Daniela, et al.. (2025). Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib. Annals of Hematology. 104(3). 2001–2004.
2.
Žáčková, Daniela, Hana Klamová, Edgar Faber, et al.. (2024). Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data. Cancer Medicine. 13(17). e70158–e70158.
3.
4.
Knight, Andrea, Martin Piskáček, Michal Jurajda, et al.. (2022). Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia. Cancer Immunology Immunotherapy. 72(5). 1209–1224. 3 indexed citations
5.
Richter, Johan, Anna Lübking, Stina Söderlund, et al.. (2021). Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI. Leukemia. 35(8). 2416–2418. 16 indexed citations
6.
Dahlén, Torsten, Germano Ferreira, Peter E. Westerweel, et al.. (2021). Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence. Blood. 138(Supplement 1). 1485–1485. 2 indexed citations
7.
8.
9.
Žáčková, Daniela, Hana Klamová, Tereza Nečasová, et al.. (2020). Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. Leukemia & lymphoma. 62(1). 194–202.
10.
Gregor, Tomáš, Michaela Kunova Bosakova, Bohumil Fafílek, et al.. (2019). Elucidation of protein interactions necessary for the maintenance of the BCR–ABL signaling complex. Cellular and Molecular Life Sciences. 77(19). 3885–3903. 10 indexed citations
11.
Saglio, Giuseppe, António Almeida, Andrija Bogdanović, et al.. (2018). Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective. Clinical Lymphoma Myeloma & Leukemia. 18(6). 375–379. 14 indexed citations
12.
Voglová, J, Zdeněk Ráčil, Daniela Žáčková, et al.. (2018). The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients. Archives of Medical Science. 14(6). 1416–1423. 14 indexed citations
13.
Ráčil, Zdeněk, Petr Cetkovský, Edgar Faber, et al.. (2014). Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study. Blood. 124(21). 1813–1813. 10 indexed citations
14.
Janíková, Andrea, et al.. (2012). Význam fyzické aktivity u pacientů s hematoonkologickými malignitami. 18(1). 2 indexed citations
15.
Rázga, Filip, Tomáš Jurček, Daniela Žáčková, et al.. (2012). Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations. Molecular Diagnosis & Therapy. 16(4). 251–259. 5 indexed citations
16.
Pavlík, Tomáš, Eva Janoušová, Zdeněk Pospı́šil, et al.. (2011). Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. BMC Medical Research Methodology. 11(1). 140–140. 4 indexed citations
17.
Žáčková, Daniela, Hana Klamová, Ladislav Dušek, et al.. (2010). Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?. American Journal of Hematology. 86(3). 318–321. 12 indexed citations
18.
Mayer, Jiřı́, Marta Krejčí, Zdeněk Pospı́šil, et al.. (2009). Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide. Experimental Hematology. 37(6). 767–773. 6 indexed citations
19.
Poláková, Kateřina Machová, Hana Klamová, Tomáš Jurček, et al.. (2009). Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Experimental Hematology. 38(1). 20–26. 18 indexed citations
20.
Hájek, Roman, Daniela Žáčková, Tomáš Büchler, et al.. (2003). Treatment of Chronic Myeloid Leukemia with Autologous. Medical Oncology. 20(1). 69–76. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simone Claudiani Breakdown of academic impact, for papers by Alicia Enrico Breakdown of academic impact, for papers by Fabian Lang Breakdown of academic impact, for papers by Jeffrey Skinner Breakdown of academic impact, for papers by Rabia Shahswar Breakdown of academic impact, for papers by Odoardo Maria Olimpieri Breakdown of academic impact, for papers by Gioia Colafigli Breakdown of academic impact, for papers by Franck E. Nicolini Breakdown of academic impact, for papers by Jana Linhartová Breakdown of academic impact, for papers by Cristina Bucelli
Rankless by CCL
2026